Plus Therapeutics (NASDAQ:PSTV) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Plus Therapeutics (NASDAQ:PSTV) posted its quarterly earnings results on Thursday. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16), Zacks reports. The company had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.19 million.

Plus Therapeutics Stock Performance

Shares of NASDAQ PSTV traded down $0.35 during midday trading on Friday, reaching $1.17. 2,276,910 shares of the stock were exchanged, compared to its average volume of 16,438,803. Plus Therapeutics has a twelve month low of $0.24 and a twelve month high of $2.67. The stock has a market capitalization of $6.92 million, a P/E ratio of -0.46 and a beta of 0.73. The company has a 50 day simple moving average of $1.11 and a 200 day simple moving average of $1.24.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on PSTV. HC Wainwright dropped their price target on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a research report on Friday. D. Boral Capital restated a “buy” rating and issued a $9.00 target price on shares of Plus Therapeutics in a report on Friday. Finally, Ascendiant Capital Markets cut their target price on Plus Therapeutics from $20.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, December 9th.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.